Lu et al. discovered that miR-23a-3p is highly expressed in sorafenib-non-responder HCC patients [390], and further proteomic analysis revealed that miR-23a-3p blocks ferroptosis by suppressing the expression of ACSL4, an essential enzyme for ferroptosis [391]. Here, ACSL4 is linked to hepatocellular carcinoma.